Blood Screening Partnerships NGI's licensed clinical laboratory status and FDA biologics licenses, combined with high throughput pooled nucleic acid testing capabilities, position it as a strategic partner for blood banks, plasma centers, and clinical trial sponsors seeking scalable infectious disease screening and quality-controlled workflows.

Infectious Disease Trials NGI already offers HIV, HAV, HBV, and HCV assays and supports clinical research; there is a sales opportunity to pursue CROs and pharma sponsors for centralized testing, infectious disease panels, and high-volume NAT testing in multicenter studies.

LabCorp Synergy As a LabCorp subsidiary NGI can be integrated into broader enterprise client relationships, enabling cross-sell of central lab services, payer-backed testing programs, and expanded geographic coverage for multicenter trials and donor screening.

Digital Reporting NGI's modern tech stack supports secure data exchange and analytics; there is value in offering API-based result reporting, EHR interfacing, and dashboards to customers for faster decision making while maintaining HIPAA-compliant data governance.

Growth Potential With mid-size scale and room to expand, NGI could broaden infectious disease panels, introduce additional NAT assays, and pursue international expansions or new regulatory licenses to capture higher-volume testing demand in research and screening markets.